Clinical Research
Hobson Prior’s clinical research team specialises in recruiting highly experienced permanent and interim clinical professionals, for a broad range of vacancies and assignments, supplying individuals and teams for office and field based roles on country specific and cross-border projects.
With expertise across all therapeutic areas, Hobson Prior’s network of clinical professionals provide support and leadership in:
-
Project Management
-
Operations Management
-
Feasibility Studies
-
Study Initiation
-
Development Planning
-
Protocol Writing
-
Investigator and Site Selection/Management
Clients
Click here for more information about us, our services, and our pan-European compliance commitment.
Candidates
Click here for information on contracting in the UK, Switzerland and Europe, and access to our contractor portal.
Hot Jobs
- Contract - Clinical Research Scientist - UK
- Kent
- up to £450 per day
- View Vacancy- Contract - Clinical Research Scientist - UK
Vacancy Search
Latest News
Anthera listing confirms weak IPO market
The disappointing public outing for Anthera Pharmaceuticals this week, eventually listing on the Nasdaq at a 50% discount to its proposed price, was not an encouraging sign for those US companies with active IPO filings at the SEC who must now be reassessing their next financing steps.
The weakness of Anthera’s IPO – $54m raised was the lowest since Cumberland Pharmaceuticals cracked open the IPO window last August – mirrors the poor performance of Omeros since it went public in October. Anthera and Omeros are both developmental stage, high risk investment opportunities, similar to five of the six companies currently pursuing an IPO. The one mature company on the list, Prometheus Laboratories, with eight marketed products and annual profits since 2005, therefore appears the standout IPO candidate, but only if it clears up uncertainty over rights to its biggest selling product (see tables below).
Investors still risk averse
Anthera was the fifth US pharmaceutical company to go public since the broader stock market recovery in the second half of 2009.
As the table below shows, the initial optimism that IPOs would start to flow has dampened as the two most recent public offerings, Anthera and Ironwood Pharmaceuticals, have only squeezed onto the market at a significant discount to the proposed price. The average discount between the filed price and the actual list price is 20%, even after some companies had already cut back their price targets.
